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. As a consequence of oxidative stress, proteins, lipids and DNA can be damaged, often resulting in structural changes. For example, when membrane phospholipids undergo lipid peroxidation, MDA and other reactive decomposition products are generated 2 . These can in turn modify endogenous molecules, generating novel oxidation-specific epitopes (OSEs), which are also present on the surface of apoptotic cells and blebs released from them 3 . Many of these OSEs are recognized as danger signals by innate immune receptors 4 . Elucidating the molecular mechanisms by which oxidative damage challenges the immune system would pave the road for new diagnostic and therapeutic approaches in several pathologies.
MDA and its condensation products are reliable markers for oxidative stress and have been associated with many disorders, including atherosclerosis 1, 4 and AMD, a degenerative disease affecting the retina that leads to irreversible vision loss 5, 6 . AMD is the most common cause of blindness in the elderly in Western societies 7 . A hallmark of developing AMD is the accumulation of extracellular deposits, termed drusen, which have been shown to contain MDA 8 . MDA-modified proteins are known to induce inflammatory responses and are recognized by innate immunity [9] [10] [11] . We recently demonstrated that OSEs in general are a major target of innate natural antibodies both in mice and humans and that ,15% of all immunoglobulin M (IgM) natural antibodies bound MDA-type adducts, suggesting a great need to defend against this specific modification 12 . However, the abundance of MDA and the danger associated with it suggests that additional, evolutionary conserved innate defence mechanisms exist.
CFH binds MDA modifications
We used an unbiased proteomic approach to identify plasma proteins binding to MDA modifications. Because normal plasma contains high titres of MDA-specific natural antibodies 12 , we purified MDAbinding proteins from plasma of atherosclerotic Rag
2/2
Ldlr 2/2 mice that lack immunoglobulins. Pooled plasma was incubated with beads coupled to either malondialdehyde-acetaldehyde (MAA)-modified or unmodified polylysine, respectively. MAA is an advanced MDAlysine adduct the structure of which is shown in Supplementary Fig. 1 (see also ref. 13 ). Bound proteins were eluted and identified by mass spectrometry. As many as 45 unique peptides were found exclusively in MAA-polylysine pull-downs, of which .55% could be attributed to CFH (Supplementary Fig. 2 and Supplementary Table 1) . CFH is a major regulator of the complement system and protects host tissues from complement-mediated damage 14 . Immunoblot analysis revealed the presence of CFH on MAA-coated beads but not on control beads (Fig. 1a) . This finding was confirmed using human plasma (Fig. 1b) . Interestingly, the anti-CFH antibody also detected lower molecular weight bands, which may represent CFH-related proteins (CFHRs) that share high sequence homology with CFH.
Using enzyme-linked immunosorbent assay (ELISA), we demonstrated that CFH bound to MDA directly and independently of the protein carrying the adducts. Purified CFH bound in a calciumindependent manner to both MAA-modified low density lipoprotein (MAA-LDL) and MAA-modified bovine serum albumin (MAA-BSA), but not to unmodified proteins ( Fig. 1c and Supplementary Fig. 3 ). Moreover, we tested binding of CFH to the oxidation-specific modifications phosphocholine-BSA (PC-BSA), which is bound by C reactive protein (CRP), as well as carboxyethylpyrrole-BSA (CEP-BSA) and 4-hydroxynonenal-BSA (4-HNE-BSA). None of these modifications were bound by CFH ( Fig. 1d and Supplementary Fig. 4A, B) . CRP and C3 were also detected in the MAA-polylysine pull-downs (Supplementary Table 1 ), but neither of them bound to coated MAA-BSA ( Fig. 1d and Supplementary Fig. 4C ).
To characterize the specificity of the binding of CFH to MDA, we performed competition assays. Only MDA-and MAA-modified LDL competed in a concentration-dependent manner for the binding of CFH to coated MAA-BSA. Neither native LDL nor the negatively charged Cu 21 -oxidized LDL showed inhibition, thereby excluding non-specific interactions mediated by charge effects (Fig. 1e) . To demonstrate a dose-dependent interaction in plasma, the binding of CFH to coated MAA-BSA was tested in different plasma dilutions ( Supplementary Fig. 5 ). Consistent with the notion that CFH is a major MDA-binding protein in plasma, binding of CFH to coated MAA-BSA was competed by soluble MAA-BSA with similar efficiency in whole plasma (Fig. 1f) . In a reciprocal experiment, binding of biotinylated MDA-LDL to immobilized purified CFH was fully competed by either MDA-or MAA-modified LDL, even at very low competitor concentrations (Fig. 1g) . In the same assay, the MDAlysine-specific monoclonal antibody MDA2 fully inhibited binding of MDA-LDL to CFH. In contrast, the apoB-100-specific monoclonal antibodies MB47 and MB24, which bind apoB-100 of MDA-LDL ( Supplementary Fig. 6 ), did not inhibit this interaction (Fig. 1h) . Using surface plasmon resonance, we observed a concentrationdependent binding of CFH to coated MAA-BSA ( Supplementary  Fig. 7 ). Taken together, these findings prove that CFH binds specifically to MDA modifications.
The CFH H402 variant has impaired MDA binding
To map the binding site for MDA on CFH, we performed binding studies using recombinantly expressed CFH fragments (Fig. 2a) . CFH is composed of 20 globular short consensus repeats (SCRs) 15 . Only fragments containing either SCR7 or SCR20 bound to coated MDA (Fig. 2a) . Reciprocally, soluble MDA-LDL only bound to immobilized fragments containing either SCR7 or SCR20, respectively (Supplementary Fig. 8 ). Importantly, these domains have also been identified as clustering points of various disease-related mutations 15 . 
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One of the most widely studied single nucleotide polymorphisms (SNPs) in CFH is the prevalent rs1061170 SNP, which causes an amino acid switch on position 402 (YRH) in SCR7. To determine the effect of the H402 substitution, we purified CFH from plasma of homozygous individuals expressing either CFH Y402 or CFH H402, respectively, and tested the binding to MDA. Compared to the common Y402 variant, the CFH variant H402 exhibited significantly impaired binding to MAA-BSA (Fig. 2b) . The H402 variant has been associated with a significant risk for the development of AMD [16] [17] [18] [19] . Therefore, we analysed the binding of CFH to coated MDA-LDL in plasma samples of AMD patients with the respective genotypes. Compared to the extent of CFH binding to MDA-LDL using plasma of individuals homozygous for the protective allele, binding in plasma of heterozygous subjects was reduced by 23% (P , 0.001), and by 52% (P , 0.001) in plasma of subjects homozygous for the H402 risk allele (Fig. 2c) , irrespective of the total plasma CFH levels ( Supplementary Fig. 9A ). Moreover, plasma levels of MDA-specific IgG and IgM antibodies were similar in all groups ( Supplementary Fig. 9B, C) .
The genetic deletion of CFHR1 and CFHR3 has been reported to protect from AMD and could influence CFH binding to MDA 20 . Less than 25% of individuals in this study carried deletions at these loci and their removal from our analysis did not alter the significance of the association of rs1061170 with MDA binding (Supplementary Fig. 9D ). Taken together, the impaired ability of the risk variant to bind MDA suggested an important role for this interaction in AMD pathogenesis.
CFH binds cellular debris via MDA epitopes
Owing to constant light exposure, the retina provides an environment that facilitates lipid peroxidation 7 . We detected MDA epitopes by immunohistochemistry in the eyes of subjects with and without AMD. MDA epitopes were detectable throughout the choroid and Bruch's membrane (Fig. 3a, d ). In eyes without AMD, labelling for MDA was stronger in the outer than inner Bruch's membrane (Fig. 3a) . In eyes with AMD, MDA staining was seen diffusely throughout Bruch's membrane (Fig. 3d ). Staining for CFH followed a similar pattern (Fig. 3b, e) . In addition, strong CFH labelling was seen in the retinal pigment epithelium (RPE) and choriocapillaris basement membranes. Moreover, the presence of C3d, a cleavage product of iC3b, indicated co-factor activity at the same sites (Fig. 3c, f) . We further demonstrated by confocal microscopy the presence of MDA epitopes on the surface of in vitro-generated necrotic RPE cells, a major cell type affected in AMD. Moreover, CFH colocalized with MDA epitopes, suggesting that MDA mediates recognition of dying cells by CFH (Fig. 3j) . To demonstrate this directly, we used flow cytometry to assess the binding of CFH to apoptotic blebs from Jurkat T cells in the presence of MAA-BSA as competitor. Consistent with the presence of MDA epitopes on only a subgroup of apoptotic blebs, we found that CFH bound between 5-45% of apoptotic blebs (Supplementary Fig. 10 ). Importantly, MAA-BSA competed for this binding by more than 60%, whereas unmodified BSA did not (Fig. 3k) . Thus, MDA adducts present in several retinal compartments and on the surface of necrotic RPE cells represent in vivo ligands for CFH. In addition, we predicted that CFH might also bind to MDA adducts in other tissues and confirmed this in atherosclerotic lesions ( Supplementary Fig. 11 ).
CFH inactivates complement on MDA-bearing surfaces
An important regulatory activity of CFH lies with its capacity to act as co-factor for serine protease factor I, thereby promoting the degradation of C3b into inactive iC3b fragments. Deposition of iC3b on apoptotic cells increases their clearance in an anti-inflammatory manner 21, 22 . We therefore tested whether CFH induces iC3b generation when bound to MDA. Indeed, CFH promoted the formation of iC3b in a dose-and time-dependent manner when bound to coated MAA-BSA (Supplementary Fig. 12) . When comparing the co-factor activity of the 402 variants on MDA-decorated surfaces, we discovered a strong functional difference in that impaired MDA-binding of the risk variant resulted in severely reduced factor-I-mediated C3 cleavage (Fig. 4a) . This activity of CFH may represent an important protective mechanism in conditions in which MDA is continuously generated, for example, on the surface of dying cells.
Importantly, other members of the CFH family such as CFHR1/ CFHR3 show homology with the carboxy terminus of CFH and therefore contain a potential MDA-binding site without possessing co-factor activity. Deletions of CFHR1/3 have been reported to be protective in AMD 20 , suggesting a negative role of these proteins in this pathology. To demonstrate the potential capacity of MDAbinding CFHR to inhibit the beneficial co-factor activity of CFH, we tested whether C-terminal CFH fragments could compete for the co-factor activity by binding to MDA. Indeed, the MDA-binding fragment SCR18-20 prevented CFH from inducing iC3b generation, whereas a non-binding fragment containing SCR15-19 had no effect RESEARCH ARTICLE (Fig. 4b) . These data point towards a complex regulation of complement activation on MDA-decorated surfaces.
CFH neutralizes proinflammatory effects of MDA
The inflammatory process in AMD lesions has been suggested to be propagated by the secretion of cytokines including IL-8 (ref. 23 ).
Stimulation of RPE cells (ARPE-19) with MAA-BSA induced the expression of IL-8 and caused an antioxidant response as indicated by upregulation of NAD(P)H dehydrogenase and hemoxygenase-1 (Fig. 5a ). We then tested the effect of CFH on MAA-LDL binding to macrophages, another cell type involved in AMD pathogenesis 24 . In a cell-based ELISA, CFH inhibited binding of MAA-LDL to thioglycollateelicited macrophages in a dose-dependent manner (Fig. 5b) . This indicates that CFH binds the same epitope on MAA-LDL that is necessary for its recognition by macrophages. Similar to ARPE-19 cells, monocytic THP-1 cells exhibited a robust expression of IL-8 following MAA-BSA stimulation. In addition, MAA-BSA induced the expression of TNF-a and IL-1b, but not IL-12b (Supplementary Fig. 13 ). Importantly, MAA-BSA-induced IL-8 secretion was inhibited by physiological concentrations of CFH in a dose-dependent manner (Fig. 5c) . In contrast, CFH had no effect on IL-8 production induced by phorbol myristate acetate ( Supplementary Fig. 14) .
To evaluate the importance of this interaction in vivo, we examined the effect of MAA adducts in a murine model. First we validated that MAA-BSA could induce secretion of KC, the mouse orthologue to human IL-8, in murine macrophages (Supplementary Fig. 15 ). To test the proinflammatory effect of MAA-BSA as well as the scavenging capacity of CFH in an AMD-relevant site, we performed intravitreal microinjections of MAA-BSA with or without CFH. After six hours mice were killed, RPE/choroid was isolated from each eye after enucleation, and RNA was extracted. The purity of the preparation was confirmed by the expression of the RPE-specific gene Rpe65 and the lack of rhodopsin (Rho) expression as a marker for the neurosensory retina in all samples (Fig. 5d) . MAA-BSA injection led to a sevenfold upregulation of KC expression in these RPE preparations, whereas BSA injection had no effect. Importantly, addition of CFH completely inhibited the effect induced by MAA-BSA (Fig. 5e) . Thus, MAA adducts promote inflammatory responses in different cell types involved in AMD in vitro and in the eye in vivo, and CFH specifically neutralizes this property.
Discussion
We report the identification of CFH as a hitherto unrecognized innate defence protein against MDA, which is a ubiquitously generated proinflammatory product of lipid peroxidation 1, 9, 10 . Our discovery of CFH as a major MDA-binding protein demonstrates that innate immunity has a pivotal role in providing homeostatic responses against endogenous oxidation-specific danger-associated molecular patterns 4 . This parallels the innate immune response to another OSE, the PC headgroup of oxidized phosphatidylcholine, mediated by the macrophage scavenger receptors CD36 and SR-B1, the murine IgM natural antibody EO6/T15 and the acute phase reactant CRP 4, 25 .
In an analogous manner, MDA is recognized by macrophage scavenger receptor SR-A 11 , several germline IgM natural antibodies 12 and-as we now demonstrate-by CFH.
CFH is one of the most abundant plasma proteins (,100-700 mg ml
21
) and the major regulator of complement activation 14 . It mediates anti-inflammatory housekeeping functions by protecting self cells from complement activation 14 , which is especially important 
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for dying cells that lose other surface-associated complement regulators 26, 27 . A number of potential ligands for CFH on host cells have been studied, including glycosaminoglycans 28 , as well as annexin A2, DNA and histones on apoptotic cells 29 . We now identify MDA as a major ligand for CFH on apoptotic/necrotic cells and show that MDA epitopes provide a surface for CFH to allow local generation of antiinflammatory iC3b fragments. This becomes relevant in situations when large amounts of cellular debris are generated. Of note, necrotic and, under certain conditions, apoptotic cells are proinflammatory per se 30, 31 . In this regard, the interaction of CFH with MDA-modified cellular compounds is also important because CFH limits MDAinduced IL-8 secretion. This provides an explanation for the ability of CFH to reduce endothelial IL-8 secretion in response to apoptotic blebs 32 . Thus, MDA epitopes are responsible for the recruitment of CFH to the surface of apoptotic cells, where it neutralizes their proinflammatory properties and halts complement activation.
We demonstrate that SCR7 and SCR20 mediate the binding of CFH to MDA. These two domains are clustering sites for mutations associated with AMD, but also other diseases 14 . The most prominent example is the H402 exchange in SCR7, which has a frequency of 35%, and may be responsible for over half of all AMD cases 33, 34 . However, direct evidence for functional consequences of this polymorphism remained elusive. Here we show that the H402 variant exhibits severely impaired binding to MDA in a gene-dosage-dependent manner, which correlates well with the H402-associated risk for developing AMD. The H402 variant has been suggested to favour local complement activation as a result of reduced binding to glycosaminoglycans in the eye 35 . However, in contrast to glycosaminoglycans, MDA is enriched in the membranes of dying cells, which are continuously generated in the retina and need to be efficiently removed 36 . By demonstrating that the H402 variant has a reduced capacity to generate antiinflammatory iC3b fragments on MDA-bearing surfaces, we provide a functional explanation for its strong disease association. It remains to be seen whether other genetic variations of CFH family members also affect MDA binding and thereby contribute to disease pathogenesis.
Consistent with an earlier report, we found MDA epitopes throughout the choroid and Bruch's membrane including drusen of AMD lesions 8 . However, even under physiological conditions, oxidized phospholipids are formed as a result of photic stimulation of retinal photoreceptors and subsequently scavenged by several processes including clearance via CD36 (ref. 37) . As one of the major degradation products of peroxidized phospholipids, MDA is continuously generated. Several lipid peroxidation products, including MDA, can cause RPE damage 38 . Therefore, physiological housekeeping mechanisms are critically needed to prevent their accumulation and adverse reactions mediated by them. Our immunohistochemical results support a role for CFH, because CFH is found in the same locations as MDA in eyes with and without AMD. We show that MDA adducts, similar to what has been shown following the ingestion of oxidized photoreceptors 23 , have the capacity to induce IL-8 secretion in RPE, which can be blocked by CFH. Increased IL-8 expression correlates with higher incidence of AMD, underlining its important pathogenic role 39 . Therefore, neutralization of MDA adducts by CFH has the potential to limit several pathogenic events in AMD.
Undoubtedly, there are multiple defences against the ubiquitous MDA adducts. The described homeostatic response may be particularly limiting in the eye, as opposed to other sites where MDA adducts accumulate such as the vascular wall 40 . Future studies need to evaluate the contribution of this newly found interaction in the pathogenesis of other inflammatory diseases. The findings described here may lead to novel approaches exploiting endogenous defence mechanisms for the prevention and therapy of chronic inflammation in general.
METHODS SUMMARY
Subjects and clinical diagnosis. The patient cohort used in this study has been described 41 .
Protein modifications. The MAA modifications of LDL, BSA or polylysine were performed as described 13 . Intravitreal injection. Intravitreal injections of BSA, MAA-BSA and/or CFH were performed in male and female C57BL/6 mice. Six hours later, the RPE/ choroid was isolated and expression of target genes assessed by quantitative RT-PCR. Bead coupling and pull-down procedure. Mouse or human plasma was incubated with polylysine or MAA-polylysine beads. Bound proteins were analysed by LC-MSMS. The interaction was verified by immunoblotting and characterized by ELISA and Biacore. Flow cytometry and immunohistochemistry. The presence of MDA epitopes and CFH was visualized by flow cytometry on apoptotic Jurkat T-cell microparticles and by immunohistochemistry for histological specimens. Co-factor assay. CFH bound to coated MAA-BSA was incubated with C3b and factor I and the generation of iC3b fragments was visualized by immunoblotting. Cell culture. Following stimulation with BSA or MAA-BSA in the presence or absence of CFH, gene expression was determined by quantitative RT-PCR and/or IL-8/KC secretion was quantified by ELISA. Binding of biotinylated MAA-LDL to peritoneal macrophages was assessed in the presence or absence of competitors as described 42 . Statistical analysis. Data are presented as mean 6 s.d. or mean 6 s.e.m. where indicated. Results were analysed by one-way analysis of variance and Student's unpaired t-test.
